Chromium picolinaye
Pro Research Analysisby 
Searched over 200M research papers for "chromium picolinaye"
Consensus Meter
Chromium Picolinate: Efficacy and Safety in Weight Loss and Metabolic Health
Chromium Picolinate for Weight Loss
Limited Impact on Weight Reduction
Chromium picolinate has been investigated for its potential to aid in weight loss. A pilot study involving 80 overweight adults found that supplementation with 1000 micrograms of chromium picolinate daily for 24 weeks did not result in significant weight loss compared to a placebo group. Both groups showed similar changes in body mass index (BMI) and central adiposity, indicating that chromium picolinate alone, or combined with nutritional education, does not significantly affect weight loss in overweight adults. A meta-analysis of randomized trials also supports this finding, suggesting a relatively small effect of chromium picolinate on body weight, with a weighted mean difference of -1.1 kg compared to placebo. However, the clinical relevance of this effect is debatable due to the lack of robustness in the results.
Chromium Picolinate and Metabolic Health
Diabetes Management and Insulin Sensitivity
Chromium picolinate has shown more promise in the management of diabetes and insulin sensitivity. A review of clinical studies involving 1,690 subjects with diabetes reported significant improvements in glycemic control, including reduced blood glucose, insulin, cholesterol, and triglyceride levels. These studies suggest that chromium picolinate can enhance insulin function and reduce the need for hypoglycemic medication, making it a valuable supplement for managing diabetes. In animal studies, chromium picolinate improved insulin sensitivity and glucose disposal in obese, hyperinsulinemic rats, indicating potential benefits for treating insulin resistance syndrome .
Effects on Lipid Profiles and Inflammatory Markers
In patients with non-alcoholic fatty liver disease (NAFLD), chromium picolinate supplementation significantly reduced triglycerides, very-low-density lipoprotein (VLDL), insulin levels, and inflammatory markers such as high-sensitivity C-reactive protein (hs-CRP) and interleukin-6 (IL-6). It also improved the quantitative insulin sensitivity check index (QUICKI), suggesting enhanced insulin sensitivity without significant changes in fasting blood sugar or cholesterol levels.
Impact on Healthy, Non-Obese Older Adults
In contrast, a study on healthy, non-obese older adults found no significant changes in insulin sensitivity, serum lipids, or body composition after 8 weeks of chromium picolinate supplementation. This indicates that the benefits of chromium picolinate may be more pronounced in individuals with existing metabolic disorders rather than in healthy populations.
Safety and Toxicity
Long-Term Safety
Long-term studies on the safety of chromium picolinate have shown that it does not induce significant changes in survival, body weight, feed consumption, or non-neoplastic lesions in rats and mice. Although there was a statistically significant increase in the incidence of preputial gland adenoma in male rats at high doses, this finding was considered equivocal. Overall, chromium picolinate was not found to be carcinogenic in these animal models, supporting its safety for long-term use.
Conclusion
Chromium picolinate appears to have limited efficacy in promoting weight loss but shows significant potential in improving glycemic control and insulin sensitivity, particularly in individuals with diabetes or insulin resistance. Its impact on lipid profiles and inflammatory markers further supports its use in managing metabolic health. While generally safe for long-term use, its benefits may be more pronounced in populations with metabolic disorders rather than in healthy individuals.
Sources and full results
Most relevant research papers on this topic